DRRX vs. JAN, PMN, APLM, MRKR, CASI, BCTX, FBIO, VYNE, IPA, and BOLT
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include JanOne (JAN), ProMIS Neurosciences (PMN), Apollomics (APLM), Marker Therapeutics (MRKR), CASI Pharmaceuticals (CASI), BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), VYNE Therapeutics (VYNE), ImmunoPrecise Antibodies (IPA), and Bolt Biotherapeutics (BOLT). These companies are all part of the "pharmaceutical preparations" industry.
JanOne (NASDAQ:JAN) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
6.3% of JanOne shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 3.0% of JanOne shares are held by company insiders. Comparatively, 4.3% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
DURECT has a consensus price target of $27.50, suggesting a potential upside of 2,494.34%. Given JanOne's higher probable upside, analysts plainly believe DURECT is more favorable than JanOne.
In the previous week, DURECT had 2 more articles in the media than JanOne. MarketBeat recorded 5 mentions for DURECT and 3 mentions for JanOne. DURECT's average media sentiment score of 0.71 beat JanOne's score of 0.51 indicating that JanOne is being referred to more favorably in the media.
JanOne has a net margin of 0.00% compared to JanOne's net margin of -323.16%. JanOne's return on equity of -316.78% beat DURECT's return on equity.
JanOne has higher revenue and earnings than DURECT.
DURECT received 316 more outperform votes than JanOne when rated by MarketBeat users.
JanOne has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Summary
DURECT beats JanOne on 8 of the 14 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
